Creso Pharma set to benefit from OTC cannabidiol sales in Australia

|

Published 01-FEB-2021 09:18 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Creso Pharma Limited (ASX:CPH; FRA: 1X8) will hit the ground running today as over-the-counter (OTC) sales of low-dose cannabidiol (CBD) products in Australian pharmacies commences.

The sale of low-dose CBD products was made possible following a decision from the Therapeutic Goods Administration (TGA) to down-schedule low-dose cannabidiol (CBD) preparations from Schedule 4 (Prescription Medicine) to Schedule 3 (Pharmacist Only Medicine).

The decision has led to CBD products containing up to a maximum of 150mg/day for use in adults that have been approved by the TGA to be sold by a pharmacist to customers without a prescription.

Products must be approved by the TGA and included on the Australian Register of Therapeutic Goods (ARTG).

This is a major development for the Australian medicinal cannabis industry and highlights a large market opportunity that is estimated to exceed $200 million per annum.

Creso Pharma’s shares have surged 700% in the last three months, but given today marks an inflection point when the group can start generating revenues from OTC sales in Australia, Creso Pharma could receive further share price support.

It is worth noting that Creso Pharma is also engaged in pre-emptive activities in advance of the relaxation of regulations in many other global jurisdictions, including the US.

Management is advancing discussions with distribution and sales groups as it prepares to expand into the US at the appropriate time.

Creso benefits from established products and distribution agreement

Creso Pharma is very well-placed to capitalise on the growing market opportunity in Australia.

The company has an existing portfolio of CBD products, currently available in Australia via prescription, including CannaQIX® 50 which is sold under the LozaCan brand.

Creso Pharma has also entered into a strategic Heads of Agreement with leading natural, sustainable health and lifestyle brand supplier Martin & Pleasance Pty Ltd (www.martinandpleasance.com) to bring Creso’s suite of cannabis-based products to the Australian market.

Martin & Pleasance has its own in-house regulatory team and an extensive workforce directly servicing over 4,000 pharmacies in Australia and New Zealand, as well as online channels, grocery and practitioner suppliers.

Creso said that discussions with Martin & Pleasance were progressing very well with both partners currently sharing information to progress potential regulatory pathways for low-dose CBD products and defining business cases, a process that will allow Creso to considerably grow its footprint with Australian pharmacies.

Highlighting the importance of this event, chairman Adam Blumenthal said, “Today is a major milestone for the Australian medicinal cannabis industry, which we anticipate will grow rapidly over the coming months.

“The TGA’s decision to allow the sale of low–dose CBD products to consumers without a prescription provides Creso Pharma with another exciting opportunity to grow in Australia and another potential revenue stream for the company.

“We will continue to work with Martin & Pleasance to define the specific regulatory pathway for our product in the Australian market and look forward to proving its superiority through the ARTG registration process.

“Creso continues to progress a number of growth initiatives in Australia and internationally, and we look forward to updating shareholders as developments materialise.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X